Search Results

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for the potential treatment of neurological disorders, today announced that Cory R. Nicholas, Ph.D., Neurona’s Co-Founder and Chief Executive Officer, is scheduled to host investor meetings at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on June 4-6, 2024.

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Manher (AJ) Joshi, M.D., as Chief Medical Officer.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Nadia Agopyan, Ph.D., RAC, as Senior Vice President of Regulatory Affairs.

Neurona Therapeutics today announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will present a corporate update on Tuesday, March 19 at 5:00 pm ET and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place on March 19-20, 2024.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that the U.S Food and Drug Administration (FDA) has granted the company’s lead product candidate, NRTX-1001, the RMAT expedited program designation for drug-resistant mesial temporal lobe epilepsy (MTLE).

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced that Cory R. Nicholas, Ph.D., Neurona’s chief executive officer, will provide a corporate update at the Oppenheimer 34th Annual Healthcare Lifesciences Conference on Wednesday, February 14 at 2:00 pm ET.

Neurona Therapeutics today announced the successful completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors.